心血管成纤维细胞显像的现状和展望  

Current status and prospect of cardiovascular fibroblast imaging

作　　者：李丽娜 杨敏福[1] Li Lina;Yang Minfu(Department of Nuclear Medicine,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China)

机构地区：[1]首都医科大学附属北京朝阳医院核医学科,北京100020

出　　处：《首都医科大学学报》2024年第1期46-51,共6页Journal of Capital Medical University

基　　金：国家自然科学基金项目(82272036);北京市医院管理中心“扬帆”计划重点医学专业项目(ZYLX202105)。

摘　　要：心肌纤维化是众多心血管疾病共同的基础病理改变,与心脏不良预后密切相关。目前临床上评价心肌纤维化的技术存在有创、特异性欠佳、无法早期诊断等不足。近年来,靶向活化成纤维细胞的核素显像因其在检测心肌纤维化以及在评估疾病进展和治疗反应方面的潜力而受到人们的关注。本文结合现有研究,重点介绍其应用现状、优势和局限性,探讨其在心血管疾病中的前景,旨在为进一步推动靶向活化成纤维细胞的核素显像在心血管疾病中的应用提供参考和启示。Myocardial fibrosis is a common pathological basis of many cardiovascular diseases and is closely related to poor prognosis of the cardiac disease.At present,there are limitations in clinical evaluation techniques for myocardial fibrosis,such as being invasive,lacking specificity,and unable to diagnose early.In recent years,nuclide imaging targeting activated fibroblasts has received attention for its potential in detecting myocardial fibrosis and in evaluating disease progression and treatment response.Based on the existing studies,the present paper focuses on its application status,advantages and limitations,and discusses its prospects in cardiovascular diseases,aiming to provide reference and inspiration to promote the application of targeted activated fibroblast radionuclide imaging in cardiovascular diseases.

关 键 词：心血管疾病 成纤维细胞活化蛋白抑制剂 心肌纤维化 分子显像 

分 类 号：R541[医药卫生—心血管疾病] R445[医药卫生—内科学]